FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry. What is presented is PEG-modified exendin or an exendin analogue containing one or more PEG derivatives (versions). One or more PEG derivatives have a branched structure (I) or (III) as specified in formula. The molar weight of one or more PEG derivatives mentioned above makes 5000 Da to 40000 Da. There are also presented a composition and a method of treating diabetes mellitus with using above PEG-modified exendin or exendin analogue.
EFFECT: presented PEG-modified exendin or exendin analogue has a prolonged blood half-life, high bioactivity and low immunogenicity.
25 cl, 10 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
| NEW VERSION OF EXENDIN OR ITS CONJUGATE | 2010 |
|
RU2528734C2 |
| SITE-SPECIFIC MONOPHYLATED ANALYGES OF EXCENDIN AND THE METHOD OF THEIR PRODUCTION | 2012 |
|
RU2625015C2 |
| STABILISED COMPOUNDS OF EXENDIN-4 | 2003 |
|
RU2376314C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| COMPOSITION COMPRISING A GLP-1 RECEPTOR AGONIST AND A GLUCAGON RECEPTOR AGONIST, AND USE THEREOF | 2016 |
|
RU2719144C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
